{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:24Z","timestamp":1788415944220,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Molecular classification has emerged as a promising tool to improve patient selection and prognostic stratification in fertility sparing treatment (FST) for endometrial cancer (EC). Although FST is currently considered a valid option for carefully selected patients with early stage, low grade endometrioid EC, recurrence rates remain substantial and conventional clinicopathologic criteria inadequately capture tumor biological heterogeneity. Current evidence suggests that NSMP tumors represent the most favorable subgroup for FST, showing the highest complete response rates and lowest recurrence rates, likely due to preserved estrogen and progesterone receptor signaling. In contrast, MMRd\/MSI H and p53abn tumors demonstrate poorer oncologic outcomes, reduced sensitivity to progestin therapy, and higher recurrence rates. Although POLEmut tumors are associated with excellent prognosis after standard surgical management, this advantage does not clearly translate into superior outcomes during hormonal treatment. Additional biomarkers, including hormone receptor expression, PI3K\/AKT\/mTOR pathway alterations, and ARID1A, CTNNB1, and ESR1 mutations, may further refine prediction of treatment response within molecular subgroups. Despite its clinical potential, the widespread implementation of molecular classification remains limited by economic and infrastructural barriers, including restricted access to sequencing technologies. Future prospective studies are needed to validate molecular guided fertility sparing strategies and to integrate molecular profiling with additional predictive biomarkers in order to optimize individualized management of young women with EC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1886770","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:10Z","timestamp":1788412450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular classification of endometrial cancer in fertility-sparing-treatment: toward a personalized clinical approach"],"prefix":"10.3389","volume":"16","author":[{"given":"Filippo Alberto","family":"Ferrari","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally Invasive Pelvic Surgery, International School of Surgical Anatomy (ISSA), IRCCS \u201cSacro Cuore - Don Calabria\u201d Hospital","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[{"name":"Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pavone","sequence":"additional","affiliation":[{"name":"IHU Strasbourg, Institute of Image-Guided Surgery","place":["Strasbourg, France"]},{"name":"Dipartimento di Scienze per la Salute della Donna e del Bambino e di Sanit\u00e0 Pubblica, IRCCS, UOC Ginecologia Oncologica","place":["Fondazione Policlinico Universitario A. Gemelli, Rome, Italy"]},{"name":"IRCAD, Research Institute Against Digestive Cancer","place":["Strasbourg, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Olearo","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Unit, Santa Croce e Carle Hospital","place":["Cuneo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Puppo","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Unit, Santa Croce e Carle Hospital","place":["Cuneo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ceccaroni","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally Invasive Pelvic Surgery, International School of Surgical Anatomy (ISSA), IRCCS \u201cSacro Cuore - Don Calabria\u201d Hospital","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines\u00ae Insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369189","article-title":"The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective","volume":"14","author":"K\u00f6gl","year":"2024","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100016","article-title":"Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"35","author":"Ferrari","year":"2025","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02203-3","article-title":"Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer","volume":"128","author":"Asami","year":"2023","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105755","article-title":"Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer","volume":"10","author":"Mastrantoni","year":"2025","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70591-6","article-title":"Classification of endometrial carcinoma: more than two types","volume":"15","author":"Murali","year":"2014","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060934","article-title":"Impact of the FIGO 2023 staging system on the adjuvant treatment of endometrial cancer: A comparative analysis with FIGO 2009","volume":"17","author":"Ferrari","year":"2025","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma\u2020,\u2021","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2019.07.013","article-title":"Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series","volume":"240","author":"Falcone","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.06.032","article-title":"Turning ProMisE into practice: Predicting response in medically managed endometrial cancers via molecular classification","volume":"159","author":"Puechl","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.810631","article-title":"Molecular classification in patients with endometrial cancer after fertility-preserving treatment: application of proMisE classifier and combination of prognostic evidence","volume":"12","author":"Ran","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2024.09.006","article-title":"Fertility-sparing treatment in MSI-H\/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis","volume":"302","author":"Zhang","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.11.006","article-title":"Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation","volume":"179","author":"Dagher","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1282356","article-title":"Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e27","article-title":"Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia","volume":"35","author":"Lv","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100024","article-title":"The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment","volume":"35","author":"De Vitis","year":"2025","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1506639","article-title":"The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial cancer: a retrospective study","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040597","article-title":"Prognostic impact of POLE exonuclease-domain mutations in endometrial cancer: A systematic review and meta-analysis","volume":"18","author":"Hurmuz","year":"2026","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263585","article-title":"The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis","volume":"17","author":"Jumaah","year":"2022","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gocm.2023.01.006","article-title":"Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment","volume":"3","author":"Wang","year":"2023","journal-title":"Gynecol Obstet Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"407.e1","DOI":"10.1016\/j.ajog.2021.05.007","article-title":"Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer","volume":"225","author":"van Weelden","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(15)33275-0","article-title":"Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications","volume":"141","author":"Ehrlich","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.012","article-title":"Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection","volume":"191","author":"Peng","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.02.020","article-title":"Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer","volume":"185","author":"Agusti","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12445","article-title":"Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia","volume":"26","author":"Wang","year":"2025","journal-title":"Biomol BioMed"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PGP.0000000000000193","article-title":"Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers","volume":"35","author":"Okoye","year":"2016","journal-title":"Int J Gynecol Pathol Off J Int Soc Gynecol Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2025.09.004","article-title":"Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease","volume":"202","author":"Sugiyama","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041593","article-title":"Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin","volume":"7","author":"Pant","year":"2012","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1095\/biolreprod.114.119255","article-title":"Influence of AKT on progesterone action in endometrial diseases","volume":"91","author":"Lee","year":"2014","journal-title":"Biol Reprod"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01829.x","article-title":"Inhibiting the PI3K\/Akt pathway reversed progestin resistance in endometrial cancer","volume":"102","author":"Gu","year":"2011","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5396","article-title":"RNA-seq and ATAC-seq analysis of CD163+ macrophage-induced progestin-insensitive endometrial cancer cells","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0655","article-title":"Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer","volume":"17","author":"Kasherman","year":"2021","journal-title":"Future Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"De Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e17611","article-title":"The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer","volume":"41","author":"Chang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2026.100978","article-title":"Estrogen receptor, GATA-3, TTF-1, and KRAS in endometrial carcinoma of no specific molecular profile: prognostic or diagnostic markers","volume":"39","author":"Siili","year":"2026","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e13","article-title":"The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification","volume":"30","author":"Guan","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4019","article-title":"Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+\/- mice","volume":"66","author":"Vilgelm","year":"2006","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ygyno.2025.05.015","article-title":"Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis","volume":"198","author":"Lam","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ajog.2025.09.041","article-title":"Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis","volume":"234","author":"Ferrari","year":"2026","journal-title":"Am J Obstet Gynecol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13586","article-title":"Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13471","article-title":"Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2392","article-title":"Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100045","article-title":"ARID1A regulates progesterone receptor expression in early endometrial endometrioid carcinoma pathogenesis","volume":"36","author":"Asaka","year":"2023","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03176-5","article-title":"Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma","volume":"479","author":"Ruz-Caracuel","year":"2021","journal-title":"Virchows Arch"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.107","article-title":"Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles","volume":"27","author":"McConechy","year":"2014","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e123","article-title":"Navigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma","volume":"36","author":"Xing","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223602","article-title":"Molecular prognosticators guiding fertility-sparing surgery in early-stage endometrial cancer: A comprehensive review","volume":"17","author":"Shaikh","year":"2025","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:11Z","timestamp":1788412451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":60,"alternative-id":["10.3389\/fonc.2026.1886770"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1886770","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1886770"}}